v1
Faculty Opinions recommendation of Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
NobleIDNI4P73W75R15S76
Type:Dataset
0 views
Embeddable Badge
[](https://nobleid.org/work/d1/20260526/ADE91CF6)
ARK Inflections
Metadata Formats
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims